Literature DB >> 1902663

Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes.

W D Irvine1, M W Johnson, E Hernandez, K R Olsen.   

Abstract

The retinal toxicity of human tissue plasminogen activator in normal rabbit eyes has recently been reported. We now report the retinal toxicity of tissue plasminogen activator in three groups of vitrectomized rabbit eyes. Group 1 underwent gas compression of the vitreous followed by tissue plasminogen activator injection in doses of 25, 50, and 100 micrograms (all doses were administered in 100 microL of fluid). Group 2 underwent lensectomy and vitrectomy followed by tissue plasminogen activator injection of 100 micrograms. Group 3 underwent lensectomy, vitrectomy, and complete fluid/gas exchange prior to injections of 12.5 and 25 micrograms of tissue plasminogen activator. Control eyes received 100 microL of balanced salt solution. In group 1, no retinal toxic reactions were observed after administration of 25 or 50 micrograms of tissue plasminogen activator, but all eyes receiving 100 micrograms demonstrated retinal damage on ophthalmoscopy, electroretinography, and light microscopy. In group 2, no retinal toxic reactions were seen after administration of 100 micrograms of tissue plasminogen activator. In group 3, two of 11 eyes receiving 25 micrograms of tissue plasminogen activator demonstrated toxic retinal changes by ophthalmoscopy, electroretinography, and light microscopy. These results suggest that gas compression of the vitreous does not significantly alter the toxic changes seen caused by tissue plasminogen activator. While lensectomy and vitrectomy appears to widen the therapeutic window for tissue plasminogen activator, the margin of safety is reduced with the addition of a large gas bubble.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902663     DOI: 10.1001/archopht.1991.01080050134044

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death.

Authors:  Shoji Notomi; Toshio Hisatomi; Takaaki Kanemaru; Atsunobu Takeda; Yasuhiro Ikeda; Hiroshi Enaida; Guido Kroemer; Tatsuro Ishibashi
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

2.  Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.

Authors:  Takeshi Mizutani; Tsutomu Yasukawa; Yuya Ito; Ayae Takase; Yoshio Hirano; Munenori Yoshida; Yuichiro Ogura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-29       Impact factor: 3.117

3.  Plasminogen activators promote excitotoxicity-induced retinal damage.

Authors:  Raghuveer S Mali; Mei Cheng; Shravan K Chintala
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

4.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

5.  Corneal electrode for recording electroretinograms in rats.

Authors:  M Rosner; P Bobak; T L Lam
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

6.  Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion.

Authors:  T H Mahmoud; Y-W Peng; A D Proia; M Davidson; V A Deramo; S Fekrat
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

7.  Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

Authors:  R P Singh; C Patel; J E Sears
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

8.  Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.

Authors:  Takuhiro Yamamoto; Motohiro Kamei; Paradee Kunavisarut; Mihoko Suzuki; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-25       Impact factor: 3.117

9.  The effect of chemical stability and purification of perfluorocarbon liquids in experimental extended-term vitreous substitution.

Authors:  M Velikay; U Stolba; A Wedrich; Y Li; P Datlinger; S Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

10.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.